Animal-to-human extrapolation of the pharmacokinetic and pharmacodynamic properties of buprenorphine

Clinical Pharmacokinetics

Volumn 46, Issue 5, 2007, Pages 433-447

  Yassen, Ashraf ^a   Olofsen, Erik ^b   Kan, Jingmin ^a   Dahan, Albert ^b   Danhof, Meindert ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE;

ALLOMETRY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; HYSTERESIS; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATION DEPRESSION; SPECIES COMPARISON;

ANALGESICS, OPIOID; ANIMALS; BUPRENORPHINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; HUMANS; MODELS, BIOLOGICAL; RATS; REPRODUCIBILITY OF RESULTS; RESPIRATORY INSUFFICIENCY;

EID: 34247590983     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746050-00005     Document Type: Article

References (28)

1. Mahmood I. Allometric issues in drug development. J Pharm Sci 1999; 88 (11): 1101-6
2. Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42 (10): 883-908
3. Van der Graaf PH, Danhof M. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35 (10): 442-6
4. Visser SA, Smulders CJ, Reijers BP, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of concentration-dependent hysteresis and biphasic electroencephalogram effects of alphaxalone in rats. J Pharmacol Exp Ther 2002; 302 (3): 1158-67
5. Zuideveld KP, Van der Graaf PH, Newgreen D, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats. J Pharmacol Exp Ther 2004; 308 (3): 1012-20
6. Rothman RB, Xu H, Wang JB, et al. Ligand selectivity of cloned human and rat opioid mu receptors. Synapse 1995; 21 (1): 60-4
7. Yassen A, Olofsen E, Dahan A, et al. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics. J Pharmacol Exp Ther 2005; 313 (3): 1136-49
8. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine in healthy volunteers. Anesthesiology 2006; 104 (6): 1232-42
9. Yassen A, Kan J, Olofsen E, et al. Mechanism-based pharmacokinetic- pharmacodynamic modeling of the respiratory depressant effect of buprenorphine and fentanyl in rats. J Pharmacol Exp Ther 2006; 319 (2): 682-92
10. Yassen A, Olofsen E, Romberg R, et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers. Clin Pharmacol Ther 2007; 81 (1): 50-8
11. Dahan A, DeGoede J, Berkenbosch A, et al. The influence of oxygen on the ventilatory response to carbon dioxide in man. J Physiol 1990; 428: 485-99
12. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco (CA): NONMEM Project Group, University of California, 1999
13. Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10 (2): 201-27
14. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30 (5): 329-32
15. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276 (5309): 122-6
16. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979; 25 (3): 358-71
17. Bullingham RE, McQuay HJ, Moore A, et al. Buprenorphine kinetics. Clin Pharmacol Ther 1980; 28 (5): 667-72
18. Knibbe CA, Zuideveld KP, Aarts LP, et al. Allometric relationships between the pharmacokinetics of propofol in rats, children and adults. Br J Clin Pharmacol 2005; 59 (6): 705-11
19. Pasternak GW. Insights into mu opioid pharmacology: the role of mu opioid receptor subtypes. Life Sci 2001; 68 (19-20): 2213-9
20. Pan L, Xu J, Yu R, et al. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005; 133 (1): 209-20
21. Ling GS, Spiegel K, Lockhart SH, et al. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 1985; 232 (1): 149-55
22. Boas RA, Villiger JW. Clinical actions of fentanyl and buprenorphine: the significance of receptor binding. Br J Anaesth 1985; 57 (2): 192-6
23. Clark AJ. General pharmacology. In: Heffner's Handbuch der experimentellen Pharmacologie Erganzungsband, Band 4. Berlin: Springer, 1937: 38-51
24. Furchgott RF. The pharmacological differentiation of adrenergic receptors. Ann N Y Acad Sci 1967; 139 (3): 553-70
25. Ohtani M, Kotaki H, Sawada Y, et al. Comparative analysis of buprenorphine- and norbuprenorphine-induced analgesic effects based on pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1995; 272 (2): 505-10
26. Galynker I, Schlyer DJ, Dewey SL, et al. Opioid receptor imaging and displacement studies with [6-O-[11C] methyl]buprenorphine in baboon brain. Nucl Med Biol 1996; 23 (3): 325-31
27. Sprenger T, Berthele A, Platzer S, et al. What to learn from in vivo opioidergic brain imaging? Eur J Pain 2005; 9 (2): 117-21
28. Nattie EE. Integrative aspects of ventral brainstem functions, ventral brainstem mechanisms and control of respiration and blood pressure. In: Trouth CO, Millis RM, Kiwull-Schone H, et al., editors. Ventral brainstem mechanisms and control functions. New York: Marcel Dekker, 1995: 253-266